Literature DB >> 18568691

General practitioners ignore high normal blood pressure.

Adam Windak1, Barbara Gryglewska, Tomasz Tomasik, Krzysztof Narkiewicz, Tomasz Grodzicki.   

Abstract

The objective of the study was to assess the ability of Polish primary care physicians to diagnose elevated blood pressure in cases with different cardiovascular risks. A questionnaire, containing eight written cases differing in relation to three major variables, was developed to conduct a survey in a stratified sample of primary health care physicians in Poland. The variables were: (i) levels of blood pressure (high normal (HN) or grade 2 hypertension (HT2); (ii) coexistence of selected risk factors (RF+/-) and (iii) diabetes mellitus (DM+/-). The response rate was 65% (125/192 selected physicians). The correct diagnosis of blood pressure (BP) level was confirmed in 54.8% of answers. The percentages of incorrectly diagnosed cases with HN BP were, respectively, 64.0% (RF-, DM-), 77.6% (RF+, DM-), 80.0% (RF+, DM+) and 84.0% (RF-, DM+). In the cases with HT2, the incorrect diagnosis ranged from 8.8% (RF+, DM-) to 20.8% (RF-, DM-). In subgroup analysis of four cases with different levels of BP, the appearance of DM significantly increased the levels of incorrect diagnosis of cases with HN BP (p<0.001). Older physicians would make an incorrect diagnosis significantly more often (r = 0.38, p<0.001). Most primary care physicians would ignore HN BP, even in diabetic patients. The age of the physician is a significant factor contributing to incorrect diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18568691     DOI: 10.1080/08037050701855822

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  1 in total

1.  Experiences of adult patients using primary care services in Poland - a cross-sectional study in QUALICOPC study framework.

Authors:  Marek Oleszczyk; Anna Krztoń-Królewiecka; Willemijn L A Schäfer; Wienke G W Boerma; Adam Windak
Journal:  BMC Fam Pract       Date:  2017-11-22       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.